A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A
Amy Miller
Primary Investigator
G
Greg Durm, MD
Primary Investigator
Overview
The purpose of this study is to compare concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin).
Description
Participants will be randomly assigned to receive radiation plus either cisplatin or nivolumab.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Oropharyngeal Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age with squamous cell carcinoma of the oropharynx.
Individuals with lifetime cumulative smoking history exceeding 10 pack-years will not be eligible.
Individuals with severe, active co-morbidity will not be eligible.
Women who are pregnant will not be eligible.
Updated on
20 Nov 2022.
Study ID: 1912360365
